Project Grant R21AG096294
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $426K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $804,450 Project Grant to the J. David Gladstone Institutes in San Francisco, CA. This grant, awarded on June 1, 2025, will fund a research project titled "Targeting NELL2 and GABAergic Dysfunction to Mitigate APOE4-Driven Pathogenesis in Alzheimer's Disease." The project aims to investigate the role of the APOE4 gene and its interaction with sex and aging in contributing to...
- The National Institute on Aging (NIA) awarded a $341,000 Project Grant (CFDA 93.866 - Aging Research) to The Roskamp Institute, Inc. in Sarasota, FL. The grant will support research to investigate the impact of the APOE4 genotype, a major genetic risk factor for Alzheimer's disease, on brain bioenergetics. The goal is to examine how APOE4-mediated disturbances in fatty acid metabolism and energy substrate availability within the cerebrovascular system and astrocytes contribute to neuronal energy...
- This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $124,786 to The Regents of the University of California, San Francisco to determine the genetic drivers of ancestry-specific differential penetrance of the APOE4 risk factor in sporadic Alzheimer's disease (AD). The research aims to pinpoint functional, ancestry-specific genetic variants within the APOE locus that may modify APOE4 expression and influence the...
- This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
- This Project Grant award of $751,442 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize and preclinically evaluate a brain-permeable CRISPR-based therapy to edit the APOE4 gene and convert it to the benign APOE3 variant in Alzheimer's disease (AD) models. The key products and services to be delivered include: Optimizing the CRISPR delivery platform using microfluidic synthetic exosomes (SE) to enhance plasma half-life and blood-brain barrier...
- This $788,121 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will fund a 5-year cross-sectional, longitudinal, and observational study to investigate the impact of Alzheimer's disease (AD) risk genes, with a focus on APOE E4, on brain function in HIV-positive older Black/African American adults. The study aims to increase understanding of Alzheimer's disease and related dementias (ADRD) risk factors in this vulnerable population, who face an increased...
- This federal Project Grant award for $528,876, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports research to investigate the cis- and trans-genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease (AD) and AD-related dementias (ADRD). The key goals of the project are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) effects for transcriptome-wide genes and proteome-wide proteins across 4 brain...
- This federal Project Grant award for $831,583 was provided by the National Institute on Aging (CFDA 93.866 Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on "Characterizing Microvascular Impairment in Adults with Elevated Genetic Risk for Alzheimer's Disease." The project aims to elucidate the physiological mechanisms by which the APOE-E4 genetic risk factor contributes to microvascular impairment,...
- This Project Grant award, funded by the National Institute on Aging's Aging Research program (CFDA 93.866), supports research to investigate how the APOE genotype affects the production and composition of mitovesicles, a type of extracellular vesicle derived from mitochondria, in the brain. The $2,499,343 award, with a performance period from Sep 1, 2024 to Aug 31, 2027, will be led by the Research Foundation for Mental Hygiene, Inc. (RFMH) at the Nathan S. Kline Institute. The project aims to...